What is Zacks Research’s Forecast for STERIS Q3 Earnings?

STERIS plc (NYSE:STE) – Analysts at Zacks Research raised their Q3 2025 earnings per share estimates for shares of STERIS in a report issued on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.30 per share for the quarter, up from their prior forecast of $2.29. The consensus estimate for STERIS’s current full-year earnings is $9.10 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.07 EPS, Q1 2026 earnings at $2.25 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.92 EPS, Q1 2027 earnings at $2.47 EPS and FY2027 earnings at $10.25 EPS.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business posted $2.03 earnings per share. STERIS’s quarterly revenue was up 7.3% on a year-over-year basis.

Several other equities research analysts have also recently weighed in on STE. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. KeyCorp boosted their target price on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. JMP Securities restated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. Stephens reiterated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. Finally, StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $262.50.

STERIS Stock Performance

STERIS stock opened at $207.98 on Friday. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS has a twelve month low of $197.82 and a twelve month high of $248.24. The company’s 50-day moving average price is $217.14 and its 200-day moving average price is $225.99. The company has a market cap of $20.53 billion, a PE ratio of 47.48 and a beta of 0.83.

Institutional Investors Weigh In On STERIS

Several hedge funds have recently made changes to their positions in the company. Bleakley Financial Group LLC raised its holdings in shares of STERIS by 8.7% in the third quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider’s stock valued at $407,000 after acquiring an additional 134 shares in the last quarter. Franklin Resources Inc. increased its position in STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after purchasing an additional 529,308 shares during the period. Assetmark Inc. raised its holdings in shares of STERIS by 24.6% in the 3rd quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock valued at $3,252,000 after purchasing an additional 2,647 shares in the last quarter. KBC Group NV lifted its position in shares of STERIS by 52.0% in the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock worth $2,928,000 after purchasing an additional 4,132 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of STERIS during the third quarter valued at approximately $9,949,000. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.14% of the company’s stock.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th were paid a $0.57 dividend. The ex-dividend date of this dividend was Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a yield of 1.10%. STERIS’s payout ratio is 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.